• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Neurodegenerative Disease Market

    ID: MRFR/LS/17671-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions), By Route of Administration (Oral, Injectable, Intravenous, Transdermal) and By Regional (North America, Europe, South America, Asia Pacific, Middl...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Neurodegenerative Disease Market Research Report -Forecast till 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Neurodegenerative Disease Market Summary

    As per Market Research Future Analysis, the Neurodegenerative Disease Market was valued at 22.1 USD Billion in 2023 and is projected to grow to 42.3 USD Billion by 2035, reflecting a CAGR of 5.56% from 2025 to 2035. The market is driven by an increasing aging population, technological advancements in treatment, rising awareness for early diagnosis, and growing investment in research and development.

    Key Market Trends & Highlights

    The Neurodegenerative Disease Market is witnessing significant growth opportunities driven by various factors.

    • Market size in 2024: 23.33 USD Billion; projected to reach 42.3 USD Billion by 2035.
    • Alzheimer's Disease market valuation in 2024: 8.0 USD Billion; expected to grow to 15.8 USD Billion by 2035.
    • Parkinson's Disease market valuation in 2024: 5.5 USD Billion; anticipated growth to 10.9 USD Billion by 2035.
    • Annual R&D spending in neuroscience exceeded 5 billion USD in recent years.

    Market Size & Forecast

    2023 Market Size USD 22.1 Billion
    2024 Market Size USD 23.33 Billion
    2035 Market Size USD 42.3 Billion
    CAGR (2025-2035) 5.56%

    Major Players

    Pfizer, Merck and Co, Biogen, Eli Lilly and Company, Roche, Novartis, Amgen, Johnson and Johnson, AstraZeneca, Teva Pharmaceutical Industries.

    Neurodegenerative Disease Market Trends

    The Neurodegenerative Disease Market is seeing significant opportunities, especially in markets involving Alzheimer's and Parkinson’s diseases. Europe and North America experience the sharpest increase in the aging population, which serves as a critical driver as the prevalence of neurodegenerative diseases increases with age. Health systems across the globe are increasing funding aimed at developing effective treatments and in-depth research, which is promising for addressing these diseases globally. Such funding invites other innovative approaches focused on improving treatment, including gene therapy and personalized medicine. 

    This market has many unexplored opportunities, particularly in developing therapies that can alter the course of the disease. Emerging biotechnology companies are racing to develop new treatment options, which can drastically change the treatment landscape. Collaborative efforts from pharmaceutical companies and research institutions are essential for clinical trial acceleration and increased treatment efficiencies. Moreover, the new-age control technologies offered by digital health and telemedicine provide significant promise for enhancing the management of neurodegenerative diseases, improving overall patient care at a global level.

    In recent years, there is a growing tendency to embrace broader approaches that emphasize enhancing a patient's quality of life, in addition to providing medical care through treatment which includes remedies for mental health issues and nutrition as well as lifestyle changes. With the shift of focus to the importance of early detection and prompt action, there is also an increase in the need for diagnostic equipment and biomarkers. In general, the Neurodegenerative Disease Market is expected to grow due to the expansion of research, rise in funding, and a more integrated strategy towards the management of these intricate disorders.

     

    The increasing prevalence of neurodegenerative diseases underscores the urgent need for innovative therapeutic strategies and comprehensive healthcare policies to address the growing burden on healthcare systems globally.

    World Health Organization (WHO)

    Neurodegenerative Disease Market Drivers

    Market Growth Projections

    The Global Neurodegenerative Disease Market Industry is poised for substantial growth, with projections indicating a market value of 23.3 USD Billion in 2024 and an anticipated increase to 42.3 USD Billion by 2035. This growth trajectory, characterized by a compound annual growth rate of 5.56% from 2025 to 2035, reflects the increasing demand for effective treatments and the ongoing advancements in research and technology. As the understanding of neurodegenerative diseases deepens, the market is likely to witness the emergence of novel therapies and diagnostic tools, further driving its expansion.

    Growing Awareness and Education

    The rising awareness and education surrounding neurodegenerative diseases significantly impact the Global Neurodegenerative Disease Market Industry. Public health campaigns and educational programs are instrumental in informing communities about the symptoms, risk factors, and available treatments for these conditions. This heightened awareness leads to earlier diagnosis and intervention, which can improve patient outcomes. As more individuals seek medical advice and treatment, the demand for effective therapies increases, contributing to market growth. The collective efforts of healthcare providers and advocacy groups are vital in shaping perceptions and driving engagement in the healthcare system.

    Government Initiatives and Funding

    Government initiatives aimed at combating neurodegenerative diseases play a crucial role in shaping the Global Neurodegenerative Disease Market Industry. Increased funding for research programs and public health campaigns is evident in various countries, reflecting a commitment to addressing these debilitating conditions. For example, national health organizations are allocating substantial budgets to support clinical trials and awareness programs. This financial backing not only fosters innovation but also encourages collaboration among stakeholders, including academic institutions and pharmaceutical companies. Such initiatives are likely to enhance the market landscape, driving growth and improving treatment accessibility.

    Advancements in Research and Development

    Ongoing advancements in research and development are propelling the Global Neurodegenerative Disease Market Industry forward. Innovative approaches, including gene therapy and personalized medicine, are being explored to address the complexities of neurodegenerative disorders. The investment in R&D is expected to yield new treatment modalities that could significantly alter disease progression. As a result, the market is anticipated to grow, with projections indicating a rise to 42.3 USD Billion by 2035. This growth is indicative of the potential breakthroughs that may emerge from current scientific endeavors, enhancing patient outcomes and quality of life.

    Technological Innovations in Diagnostics

    Technological innovations in diagnostics are transforming the Global Neurodegenerative Disease Market Industry. Advanced imaging techniques and biomarker discovery are enhancing the ability to diagnose neurodegenerative diseases at earlier stages. These innovations not only facilitate timely interventions but also improve the understanding of disease mechanisms, which is crucial for developing targeted therapies. As the market evolves, the integration of artificial intelligence and machine learning in diagnostic processes is expected to further refine accuracy and efficiency. This trend may lead to a more proactive approach in managing neurodegenerative diseases, ultimately benefiting patients and healthcare systems alike.

    Rising Prevalence of Neurodegenerative Diseases

    The increasing incidence of neurodegenerative diseases, such as Alzheimer's and Parkinson's, is a primary driver of the Global Neurodegenerative Disease Market Industry. As populations age, the number of individuals affected by these conditions rises significantly. For instance, it is projected that by 2024, the market will reach 23.3 USD Billion, reflecting the urgent need for effective treatments and interventions. This trend underscores the necessity for healthcare systems to adapt and allocate resources towards research and development, thereby influencing market dynamics and fostering innovation in therapeutic options.

    Market Segment Insights

    Neurodegenerative Disease Market Disease Type Insights

    The Neurodegenerative Disease Market, primarily categorized by Disease Type, is set for significant growth as it reflects a variety of disorders characterized by progressive degeneration of the nervous system. In 2024, the market valued at 23.33 USD Billion and is projected to rise to 42.3 USD Billion by 2035.

    Among the diseases categorized under this segment, Alzheimer's Disease emerges as a notable contributor, accounting for a market valuation of 8.0 USD Billion in 2024 and is expected to reach 15.8 USD Billion by 2035, marking it as a key component in the overall market and reflecting the growing recognition of this disease's burden on healthcare systems globally.

    Following closely, Parkinson's Disease a significant position in the market, with a valuation of 5.5 USD Billion in 2024 and anticipated growth to 10.9 USD Billion in 2035. This condition, which affects movement control, is critical not just for patients but also for caregivers, demonstrating the extensive social and economic impact of neurodegenerative diseases.

    Multiple Sclerosis is another considerable contributor, valued at 4.0 USD Billion in 2024 and expected to grow to 8.0 USD Billion by 2035, signifying the urgency in research and treatment development for this autoimmune disorder that affects the central nervous system.In comparison, Amyotrophic Lateral Sclerosis (ALS) is on a smaller scale, valued at 2.0 USD Billion in 2024 and projected to reach 4.0 USD Billion in 2035, highlighting the need for attention in therapeutic advancements for this rapidly progressing disease. 

    Meanwhile, Huntington's Disease treatment showcases a contrasting pattern, valued at 3.83 USD Billion in 2024, albeit with a projected decrease to 3.6 USD Billion by 2035, indicating unique challenges in both treatment and management. The disease type segmentation presents various opportunities for market players, with major growth drivers including an aging global population, increasing healthcare expenditure, and heightened awareness regarding neurodegenerative diseases, which are pivotal for driving research funding and innovation in therapeutic solutions.

    Neurodegenerative Disease Market Diagnosis Method Insights

    The Neurodegenerative Disease Market, particularly concerning the Diagnosis Method segment, represents a critical area with significant growth prospects. 2024, this market reach a valuation of 23.33 USD Billion, reflecting the increasing demand for effective diagnostic tools. Diagnosis methods such as Neurological Examination and Imaging Techniques play a pivotal role in accurately identifying neurodegenerative diseases, enhancing the capabilities of healthcare providers in early detection and treatment planning. Imaging Techniques offer advanced visualization of brain structures and functions, crucial for diagnosing conditions such as Alzheimer's and Parkinson's diseases.

    Moreover, Cerebrospinal Fluid Analysis and Electrophysiological Tests are vital in understanding neurological impairments, offering insights into underlying pathological mechanisms. The growing prevalence of neurodegenerative disorders and the increasing geriatric population are key drivers for market growth, with the Neurodegenerative Disease Market statistics pointing towards a sustained interest and investment in Research and Development. 

    Challenges include the complexity of disease manifestations and the need for more accessible diagnostic modalities, yet significant opportunities exist for innovation in diagnostic technology.This landscape highlights the importance of continuous advancements in diagnostic methodologies for improving patient outcomes globally.

    Neurodegenerative Disease Market Treatment Type Insights

    The Neurodegenerative Disease Market focuses heavily on the Treatment Type segment, which plays a crucial role in addressing various conditions affecting the nervous system. In 2024, the overall market valued at 23.33 USD Billion, reflecting the growing demand for innovative treatment options. The Treatment Type segmentation includes Medication, Therapy, Rehabilitation, and Surgical Interventions, with Medication often dominating due to its fundamental role in managing symptoms and modifying disease progression. Therapy encompasses diverse approaches, including physical and occupational practices vital for enhancing patient quality of life.

    Rehabilitation services are increasingly recognized for their necessity in restoring functional abilities, while Surgical Interventions serve as a critical option for specific cases requiring more invasive techniques. As the Neurodegenerative Disease Market statistics indicate a rising prevalence of disorders like Alzheimer's and Parkinson's diseases, the push for effective treatment methodologies will drive growth in these segments. 

    Trends such as enhanced Research and Development efforts, coupled with growing awareness of neurodegenerative diseases, further accentuate the importance of these treatment types in global healthcare strategies.Additionally, opportunities arise from advancements in technology and innovative methodologies that promise better patient outcomes in this segment, thus shaping the future landscape of the Neurodegenerative Disease Market.

    Neurodegenerative Disease Market Route of Administration Insights

    The Route of Administration segment in the Neurodegenerative Disease Market is crucial for delivering effective therapies to patients. 2024, the overall market valued at 23.33 USD Billion, reflecting significant growth in the industry. The segmentation within this category includes Oral, Injectable, Intravenous, and Transdermal methods, each playing a vital role in treatment delivery. Oral administration is often preferred for its convenience and patient's adherence, while Injectable routes have gained importance for delivering biologics directly into the system, thereby enhancing efficacy.

    Intravenous administration allows for immediate therapeutic action, proving essential in acute situations. Transdermal routes are becoming popular for continuous drug delivery, improving patient compliance and minimizing side effects. Collectively, these routes not only enhance the effectiveness of therapies but also align with market growth trends driven by advancements in drug formulation and technology. With an expected Compound Annual Growth Rate (CAGR) of 5.56 from 2025 to 2035, the Neurodegenerative Disease Market shows promising potential for innovation and development in treatment methodologies across the globe.

    Get more detailed insights about Neurodegenerative Disease Market Research Report -Forecast till 2035

    Regional Insights

    The Neurodegenerative Disease Market exhibits diversified growth across various regions, collectively reach a valuation of 23.33 USD Billion 2024. North America is the dominant player, holding a valuation of 9.0 USD Billion in 2024, and is projected to grow significantly to 16.4 USD Billion by 2035, driven by advanced Research and Development and a high prevalence of neurodegenerative conditions. Europe follows closely with a valuation of 7.0 USD Billion in 2024, increasing to 12.7 USD Billion in 2035, highlighting the region's robust healthcare infrastructure and increased awareness.

    The Asia-Pacific (APAC) region also witness notable growth, with a market value of 4.5 USD Billion in 2024, projected to rise to 8.5 USD Billion by 2035, fueled by a rising aging population and improving healthcare access. Meanwhile, South America and the Middle East and Africa (MEA) are projected to hold market valuations of 1.5 USD Billion and 1.33 USD Billion in 2024, respectively, with estimates reaching 2.8 USD Billion and 2.0 USD Billion by 2035. 

    Though smaller in comparison, these regions show significant potential for growth due to increasing investment in healthcare and awareness of neurodegenerative diseases.Overall, the Neurodegenerative Disease Market segmentation illustrates a landscape filled with opportunities for innovation and market expansion.

    Neurodegenerative Disease Market Region

    Key Players and Competitive Insights

    The Neurodegenerative Disease Market is characterized by rapid advancements and intense competition as key players strive to innovate and deliver effective treatment options for progressive conditions such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS). This market is driven by rising incidences of these diseases, increasing awareness about neurodegenerative disorders, and a growing elderly population worldwide. 

    The competitive landscape highlights various strategies employed by pharmaceutical companies, including mergers, acquisitions, and the development of novel therapies, that aim to address the unmet medical needs of patients. Ongoing research and development efforts are paramount, with many companies investing heavily in clinical trials to bring potential therapies and solutions to the market. Collaborations with research institutions and academia are also common as firms seek to leverage cutting-edge science and technology in their product offerings.

    Pfizer boasts a significant presence in the Neurodegenerative Disease Market, leveraging its robust RD capabilities and extensive portfolio that encompasses various therapeutic areas, including neurology. The company has a noteworthy track record of innovation, which has solidified its position among the market leaders. Pfizer's strengths lie in its established global distribution network and partnerships that enhance its ability to reach various markets efficiently. With a commitment to addressing the growing challenges of neurodegenerative diseases, Pfizer is actively involved in multiple clinical trials that aim to deliver breakthrough therapies.

    The company's sizable investment in neuroscience has allowed it to pursue a pipeline of promising treatments aimed at slowing the progression of neurodegenerative diseases, showcasing its dedication to improving patient outcomes on a global scale.

    Merck and Co has emerged as a compelling competitor in the Neurodegenerative Disease Market, with a diverse range of products targeting symptoms and progression associated with neurodegenerative disorders. The company's commitment to research has resulted in key innovations and therapeutic advancements in the treatment of these conditions. Merck and Co's strengths include its strong market presence, established relationships with healthcare providers, and a commitment to enhancing patient access to therapies. 

    The company has engaged in strategic mergers and acquisitions, enabling it to broaden its pipeline and leverage synergies with other players in the field. Merck and Co's leading products focus on addressing the complexities of neurodegeneration, while ongoing collaborations with academic institutions position it favorably for future growth. The company's global reach is further emphasized by its active participation in international clinical trials, ensuring a comprehensive approach to tackling neurodegenerative diseases worldwide and meeting the urgent needs of affected populations.

    Key Companies in the Neurodegenerative Disease Market market include

    Industry Developments

    Recent developments in the Neurodegenerative Disease Market have showcased significant advancements and strategic movements among key players. For instance, Biogen received strong attention following the launch of its new Alzheimer's treatment, which could potentially reshape therapeutic protocols globally. Additionally, Elo Lilly and Company has reported advancements in its research pipeline focusing on new treatments for Alzheimer's, reflecting an ongoing commitment to address this challenging market. 

    In terms of mergers and acquisitions, in August 2023, Amgen announced its acquisition of a smaller biotech firm specializing in neurodegenerative disorders, enhancing its portfolio in this therapeutic area. Furthermore, in June 2023, Pfizer and Roche formed a partnership to develop groundbreaking therapies targeting multiple neurodegenerative conditions, which has been widely anticipated in the market. 

    The ongoing presence of robust Pharmaceutical Research and Development initiatives has led to a surge in market valuation, positively impacting the Neurodegenerative Disease Market. These developments, along with increasing investment in technology-driven solutions for patient care, signify the growing focus on battling these debilitating diseases on a worldwide scale.

    Future Outlook

    Neurodegenerative Disease Market Future Outlook

    The Global Neurodegenerative Disease Market is projected to grow at a 5.56% CAGR from 2024 to 2035, driven by advancements in therapeutics, increasing prevalence, and heightened research funding.

    New opportunities lie in:

    • Develop personalized medicine approaches targeting specific neurodegenerative conditions.
    • Invest in digital health technologies for remote patient monitoring and management.
    • Expand clinical trial networks to accelerate drug development and approval processes.

    By 2035, the market is expected to exhibit robust growth, reflecting advancements in treatment and increased patient access.

    Market Segmentation

    Neurodegenerative Disease Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Neurodegenerative Disease Market Disease Type Outlook

    • Alzheimer's Disease
    • Parkinson's Disease
    • Multiple Sclerosis
    • Amyotrophic Lateral Sclerosis
    • Huntington's Disease

    Neurodegenerative Disease Market Treatment Type Outlook

    • Medication
    • Therapy
    • Rehabilitation
    • Surgical Interventions

    Neurodegenerative Disease Market Diagnosis Method Outlook

    • Neurological Examination
    • Imaging Techniques
    • Cerebrospinal Fluid Analysis
    • Electrophysiological Tests

    Neurodegenerative Disease Market Route of Administration Outlook

    • Oral
    • Injectable
    • Intravenous
    • Transdermal

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 22.1(USD Billion)
    MARKET SIZE 2024 23.33(USD Billion)
    MARKET SIZE 2035 42.3(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 5.56% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Pfizer, Merck and Co, Sony Corporation, Sage Therapeutics, Roche, AbbVie, Johnson and Johnson, Biogen, Teva Pharmaceutical Industries, Vifor Pharma, Novartis, AstraZeneca, Amgen, Eli Lilly and Company, Sanofi
    SEGMENTS COVERED Disease Type, Diagnosis Method, Treatment Type, Route of Administration, Regional
    KEY MARKET OPPORTUNITIES Innovative drug development, Biomarker discovery advancements, Telehealth solutions expansion, Personalized medicine trends, Increased public awareness campaigns
    KEY MARKET DYNAMICS Aging population increase, Rising prevalence rates, Advancements in treatment options, Growing awareness initiatives, Increased R&D investment
    COUNTRIES COVERED North America, Europe, APAC, South America, MEA

    FAQs

    What is the projected market size of the Global Neurodegenerative Disease Market in 2024?

    The Global Neurodegenerative Disease Market is expected to be valued at 23.33 USD Billion in 2024.

    What is the expected market size for Alzheimer's Disease by 2035?

    The market size for Alzheimer's Disease is projected to reach 15.8 USD Billion by 2035.

    Which region is expected to dominate the Global Neurodegenerative Disease Market in 2024?

    North America is expected to dominate the market with a valuation of 9.0 USD Billion in 2024.

    What is the expected CAGR for the Global Neurodegenerative Disease Market from 2025 to 2035?

    The market is projected to grow at a CAGR of 5.56% from 2025 to 2035.

    What will the market value for Parkinson's Disease be in 2035?

    The market value for Parkinson's Disease is anticipated to be 10.9 USD Billion in 2035.

    Who are the major players in the Global Neurodegenerative Disease Market?

    Key players include Pfizer, Merck and Co, Roche, Johnson and Johnson, and Biogen.

    What is the market size for Multiple Sclerosis in 2024?

    The market size for Multiple Sclerosis is expected to reach 4.0 USD Billion in 2024.

    What are the expected market values for Amyotrophic Lateral Sclerosis in 2024 and 2035?

    The market valuation for Amyotrophic Lateral Sclerosis is expected to be 2.0 USD Billion in 2024 and 4.0 USD Billion in 2035.

    How much is the Global Neurodegenerative Disease Market expected to be valued at in Europe by 2035?

    The market in Europe is expected to be valued at 12.7 USD Billion by 2035.

    What will the market size for Huntington's Disease be in 2024?

    The projected market size for Huntington's Disease is 3.83 USD Billion in 2024.

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials